221 related articles for article (PubMed ID: 31707040)
1. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy.
Karanam NK; Ding L; Aroumougame A; Story MD
Transl Res; 2020 Mar; 217():33-46. PubMed ID: 31707040
[TBL] [Abstract][Full Text] [Related]
2. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines.
Karanam NK; Srinivasan K; Ding L; Sishc B; Saha D; Story MD
Cell Death Dis; 2017 Mar; 8(3):e2711. PubMed ID: 28358361
[TBL] [Abstract][Full Text] [Related]
3. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
Mumblat H; Martinez-Conde A; Braten O; Munster M; Dor-On E; Schneiderman RS; Porat Y; Voloshin T; Davidi S; Blatt R; Shteingauz A; Tempel-Brami C; Zeevi E; Lajterer C; Shmueli Y; Danilov S; Haber A; Giladi M; Weinberg U; Kinzel A; Palti Y
Lung Cancer; 2021 Oct; 160():99-110. PubMed ID: 34482104
[TBL] [Abstract][Full Text] [Related]
4. Replication fork stability confers chemoresistance in BRCA-deficient cells.
Ray Chaudhuri A; Callen E; Ding X; Gogola E; Duarte AA; Lee JE; Wong N; Lafarga V; Calvo JA; Panzarino NJ; John S; Day A; Crespo AV; Shen B; Starnes LM; de Ruiter JR; Daniel JA; Konstantinopoulos PA; Cortez D; Cantor SB; Fernandez-Capetillo O; Ge K; Jonkers J; Rottenberg S; Sharan SK; Nussenzweig A
Nature; 2016 Jul; 535(7612):382-7. PubMed ID: 27443740
[TBL] [Abstract][Full Text] [Related]
5. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells.
Giladi M; Munster M; Schneiderman RS; Voloshin T; Porat Y; Blat R; Zielinska-Chomej K; Hååg P; Bomzon Z; Kirson ED; Weinberg U; Viktorsson K; Lewensohn R; Palti Y
Radiat Oncol; 2017 Dec; 12(1):206. PubMed ID: 29284495
[TBL] [Abstract][Full Text] [Related]
6. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.
Jo Y; Kim EH; Sai S; Kim JS; Cho JM; Kim H; Baek JH; Kim JY; Hwang SG; Yoon M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469352
[TBL] [Abstract][Full Text] [Related]
7. An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications.
Karanam NK; Story MD
Int J Radiat Biol; 2021; 97(8):1044-1054. PubMed ID: 33086019
[TBL] [Abstract][Full Text] [Related]
8. Tumor treating fields: a new frontier in cancer therapy.
Davies AM; Weinberg U; Palti Y
Ann N Y Acad Sci; 2013 Jul; 1291():86-95. PubMed ID: 23659608
[TBL] [Abstract][Full Text] [Related]
9. Tumor treating fields: concept, evidence and future.
Pless M; Weinberg U
Expert Opin Investig Drugs; 2011 Aug; 20(8):1099-106. PubMed ID: 21548832
[TBL] [Abstract][Full Text] [Related]
10. Theory and application of TTFields in newly diagnosed glioblastoma.
Yu A; Zeng J; Yu J; Cao S; Li A
CNS Neurosci Ther; 2024 Mar; 30(3):e14563. PubMed ID: 38481068
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
12. Gastric cancer associated variant of DNA polymerase beta (Leu22Pro) promotes DNA replication associated double strand breaks.
Rozacky J; Nemec AA; Sweasy JB; Kidane D
Oncotarget; 2015 Sep; 6(27):24474-87. PubMed ID: 26090616
[TBL] [Abstract][Full Text] [Related]
13. DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells.
Vanderlinden A; Jones CG; Myers KN; Rominiyi O; Collis SJ
Br J Cancer; 2023 Nov; 129(11):1829-1840. PubMed ID: 37777579
[TBL] [Abstract][Full Text] [Related]
14. Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.
Wang Y; Pandey M; Ballo MT
Oncologist; 2019 Dec; 24(12):e1426-e1436. PubMed ID: 31444292
[TBL] [Abstract][Full Text] [Related]
15. Tumour treating fields in a combinational therapeutic approach.
Branter J; Basu S; Smith S
Oncotarget; 2018 Nov; 9(93):36631-36644. PubMed ID: 30564303
[TBL] [Abstract][Full Text] [Related]
16. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
Murai J
Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
[TBL] [Abstract][Full Text] [Related]
17. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo.
Giladi M; Weinberg U; Schneiderman RS; Porat Y; Munster M; Voloshin T; Blatt R; Cahal S; Itzhaki A; Onn A; Kirson ED; Palti Y
Semin Oncol; 2014 Oct; 41 Suppl 6():S35-41. PubMed ID: 25213867
[TBL] [Abstract][Full Text] [Related]
18. Can tumor treating fields induce DNA damage and reduce cell motility in medulloblastoma cell lines?
Nitta RT; Luo EJ; Lim M; Li G
J Neurosurg Pediatr; 2022 Dec; 30(6):555-566. PubMed ID: 36208441
[TBL] [Abstract][Full Text] [Related]
19. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
20. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells.
Giladi M; Schneiderman RS; Voloshin T; Porat Y; Munster M; Blat R; Sherbo S; Bomzon Z; Urman N; Itzhaki A; Cahal S; Shteingauz A; Chaudhry A; Kirson ED; Weinberg U; Palti Y
Sci Rep; 2015 Dec; 5():18046. PubMed ID: 26658786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]